Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.20 and traded as low as $0.1667. Northwest Biotherapeutics shares last traded at $0.1702, with a volume of 18,376,200 shares traded.

Northwest Biotherapeutics Price Performance

The stock has a market capitalization of $285.35 million, a PE ratio of -0.01 and a beta of -0.61. The company has a 50 day moving average price of $0.18 and a 200-day moving average price of $0.20.

Get Northwest Biotherapeutics alerts:

Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The company had revenue of $0.81 million during the quarter.

Hedge Funds Weigh In On Northwest Biotherapeutics

A hedge fund recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC purchased a new position in Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned approximately 0.07% of Northwest Biotherapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.04% of the company’s stock.

Northwest Biotherapeutics Company Profile

(Get Free Report)

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.

Featured Articles

• Five stocks we like better than Northwest Biotherapeutics
• Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
• J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
• Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
• GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test

Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.